ASCO 2023 | HRQoL and pain outcomes in mCRPC: abi + ala vs abi + pbo in PROpel

Andrew J. Armstrong, MD, MSc, Duke Cancer Institute, Durham, NC, shares the health-related quality of life (HRQoL) and pain outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone and olaparib versus abiraterone and placebo in the Phase III PROpel trial (NCT03732820). The primary analysis demonstrated a significant improvement in radiographic progression-free survival (rPFS) with abiraterone acetate plus olaparib compared to abiraterone acetate plus placebo (median 24.8 vs 16.6 months, hazard ratio 0.66). In this final analysis, the OS data were presented, showing no meaningful difference between the two arms. The trial also assessed time to pain progression (TTPP) and symptomatic skeletal related events (SSRE) as secondary endpoints, and no significant differences were observed. Importantly, HRQoL measures, including FACT-P scores and pain assessments, showed no clinically meaningful differences between the two treatment arms. These findings suggest that the combination of abiraterone acetate plus olaparib provides clinical benefit without negatively impacting HRQoL compared to the standard-of-care treatment. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.